ADM Wins Health Innovation Award at Fi Europe with Lactobacillus gasseri CP2305 Postbiotic
At the 30th edition of Fi Europe, ADM was recognized as a leading innovator in health and wellness. ADM's newest introduction to its postbiotic suite, Lactobacillus gasseri CP2305, was named the winner of the Health Innovation Award category during the Fi Europe Innovation Award ceremony on December 2, 2025.
This year's Fi Europe Innovation Awards celebrated excellence and breakthroughs in the food and beverage industry. ADM was among the six winners, which were selected from 23 finalists by an 11-member expert judging panel. In addition to ADM winning the Health Innovation Award category, ADM was also a finalist in the Sustainability Innovation Award category for its regenerative agriculture collaborations across Europe.
"We're honored to have Lactobacillus gasseri CP2305 postbiotic and our dedication to furthering research and solutions within the microbiome recognized on such an important stage," said Marie-Bénédicte Charpentier, Health & Wellness Marketing Director, EMEA, ADM. "Year after year, Fi Europe has grown into an incredible space for industry leaders to connect and share their cutting-edge solutions. We're proud to have L. gasseri CP2305 postbiotic celebrated at Fi Europe."
"Winning this award is particularly important as it really does reinforce ADM's position as a leader in the postbiotic space," said Richard Day, Vice President, Medical Affairs and Clinical Development, ADM. "We continue to invest heavily in innovation across the biotics space, and this award recognizes the strength of the science that underpins our postbiotic portfolio."
This win is particularly significant as consumers demand more functional food and supplement options to support their sleep quality and mood and reduce their stress. ADM's recently published proprietary consumer insights finds there is a substantial sleep satisfaction gap, along with a growing understanding of the interconnection between sleep quality and emotional well-being.
"Through our collaboration with Asahi Group, we introduced L. gasseri CP2305 postbiotic into our vast health and wellness solutions portfolio, bringing its game-changing tailored support via the gut-brain axis to consumers across the globe. It is backed by eight clinical trials demonstrating potential support for sleep quality, along with stress and mood management. As a postbiotic, L. gasseri CP2305 can withstand tough formulation environments, supporting new, consumer-preferred innovations within functional foods and supplements," said Charpentier.
Research suggests supplementing one's diet with L. gasseri CP2305 postbiotic may support emotional well-being, may support reduced stress, and may be associated with better sleep efficiency, reduced time to fall asleep/sleep latency, healthy overall sleep quality and improved total sleep duration1,2,3. L. gasseri CP2305 postbiotic may also be associated with sleep efficiency, duration and time to fall asleep based on validated questionnaires1,2,3, with two trials supporting the data using objective measures (electro-encephalograph)2,3.
Additional clinical studies specifically examined L. gasseri CP2305 postbiotic for supporting stress and mental well-being for women and men, throughout various life stages:
• In one trial on women's health, results found that L. gasseri CP2305 postbiotic may support positive moods and reduce stress/anxiety in healthy young women (with an average age of 21.5) experiencing premenstrual symptoms4.
• A second clinical study showed L. gasseri CP2305 postbiotic may support positive changes in physiological and emotional parameters in women experiencing menopause based on two validated questionnaires5.
• L. gasseri CP2305 postbiotic may also support reduced levels of stress and occasional fatigue associated with exercise, may support improved stress levels in male athletes, may support improved recovery from exercise in male athletes and may help support positive mitochondrial function6.
L. gasseri CP2305 postbiotic was also recognized at the 2025 Gulfood Manufacturing Industry Excellence Awards, where it was named Functional Ingredient of the Year. Additionally, ADM also won the Health Innovation Award at the 2024 Fi Europe Innovation Awards with its heat-treated postbiotic Bifidobacterium longum CECT 7347 (HT-ES1*).
Learn more about ADM's award-winning L. gasseri CP2305 postbiotic here, and ADM’s wider portfolio of next-generation microbiome solutions here.
1Nishida, K., et al., (2017) Journal of Applied Microbiology 123:1561-1570
2Nishida, K., et al., (2017) Journal of Functional Foods 36:112–121
3Nishida, K., et al., (2019) Nutrients 11:1859
4Nishida, K., et al., (2021) Journal of Functional Foods 80:104426
5Sawada, D., et al., (2022) Nutrients, 14:1695
6Sawada, D., et al., (2019) Journal of Functional Foods 57:465–476
*Bifidobacterium longum CECT7347 (ES1) is used by ADM Biopolis under license from CSIC.